Delivery Order SPE2DB22D3501-SPE2DB25FTN11

Award Date 11/18/24
Potential Completion Date 12/10/24
Potential Value $19K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,722.57 firm-fixed-price delivery order is for the supply of REVLIMID 25 MG CAPSULE 21S, a specialty pharmaceutical product. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary vehicle for...
This is a federal contract award made by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $74,890.20 firm fixed-price delivery order is for the supply of REVLIMID 10 MG CAPSULE 28S, a prescription medication. The award has an ultimate completion date of May 5, 2025. This delivery order is part of a larger Indefinite Delivery Contract (IDC) the company holds with DLA Troop Support Medical, valued at...
This federal contract award, valued at $24,963.40, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm-fixed-price delivery order is for the supply of REVLIMID 5 MG CAPSULE 100S, a pharmaceutical product. The contract has an ultimate completion date of February 24, 2025. Amerisourcebergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
This federal contract award, valued at $18,722.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Firm Fixed Price Delivery Order for the supply of REVLIMID 15 MG CAPSULE 21S, a prescription medication. The contract has an ultimate completion date of March 12, 2025 and was awarded on February 19, 2025. This contract award is associated with a larger Indefinite Delivery...
This federal contract award, valued at $18,722.57, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a Delivery Order under a broader Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The contract provides for the delivery of 4567313172 - REVLIMID 25 MG CAPSULE 21S, a pharmaceutical product, to...
This is a federal contract award from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of REVLIMID 10 MG CAPSULE 28S, a prescription medication, with a ceiling value of $74,890.20. The contract is a Firm Fixed Price Delivery Order with an ultimate completion date of April 8, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) that AmerisourceBergen holds...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $89,155.06 firm fixed-price delivery order contract is for the supply of REVLIMID 15 MG CAPSULE 100S, a prescription medication. The contract does not have a set-aside designation, indicating open competition. Amerisourcebergen Drug Corp is the prime contractor for this award, which is associated with a larger...
This is a federal contract award valued at $178,310.12 from the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order for the supply of REVLIMID 10 MG CAPSULE 100S, a prescription medication. The contract is a firm fixed-price agreement with a period of performance through January 24, 2025. It is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite...
This is a $103,758.92 firm fixed-price delivery order awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of REVLIMID 5 MG CAPSULE 100S. The award has an ultimate completion date of July 14, 2025 and is not set aside. Amerisourcebergen Drug Corp holds a significant $999,999,999.00 Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated as SPE2DX, which provides a comprehensive global pharmaceutical...
  • SPE2DB22D3501
    Indefinite Delivery Contract
  • SPE2DB22D3501-SPE2DB25FTN11
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $18,722.57 firm-fixed-price delivery order is for the medical product REVLIMID 25 MG CAPSULE 21S, with a period of performance through December 10, 2024.

The award is associated with a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. No set-aside designation was used for this specific award.

Generated 2/17/25, 9:41 PM